Drug Profile
MLN 608
Alternative Names: MLN608Latest Information Update: 08 Jun 2006
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 08 Jun 2006 No development reported - Preclinical for Glioblastoma in USA (unspecified route)
- 19 Feb 2003 Preclinical trials in Glioblastoma in USA (unspecified route)